Molecular circulating tumor DNA response to identify long-term survival in patients receiving immunotherapy with initial radiologic stable disease

Autor:	Shaad Essa Abdullah, Phillip A. Dennis, Chen Gao, Jamie E. Chaft, Matthew D. Hellmann, Brandon W. Higgs, Qu Zhang, Neil H. Segal
Rok vydání:	2019
Předmět:	Cancer Research business.industry medicine.medical_treatment Immunotherapy Complement (complexity) Stable Disease Oncology Circulating tumor DNA Long term survival Immunology medicine In patient business hormones hormone substitutes and hormone antagonists
Zdroj:	Journal of Clinical Oncology. 37:2546-2546
ISSN:	1527-7755 0732-183X
Popis:	2546 Background: Early on-treatment changes in ctDNA may identify responders to immunotherapy and complement radiologic assessment of benefit. Here we investigate how early changes in ctDNA associate with long-term survival following treatment with immunotherapy, and if differential patterns in molecular ctDNA response (MCR) among patients with radiologic stable disease (SD) at first on-treatment scan could identify patients deriving benefit from treatment. Methods: Paired pre- and on-treatment (week 6-8) plasma samples from 3 cohorts of patients treated with durvalumab (D) +/- tremelimumab (D+T) were evaluated (NCT01693562, NCT02087423, NCT02261220). CtDNA was profiled with the 73-gene Guardant 360 assay. Nonsynonymous variants were summarized per patient to calculate variant allelic frequency changes (dVAF) and on-treatment variant allele frequency (pVAF). A combination of dVAF and pVAF was used to define MCR. Results: The reduction of ctDNA (dVAF
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::62429890c2aa539113f69087e32c5542 https://doi.org/10.1200/jco.2019.37.15_suppl.2546 Zobrazit plný text záznamu